Part of his professional duties included designing websites for his employers until he retired in 2012. He quickly became the “goto person” for computer problems and eventually the IT manager. He later worked as a draftsman in Machine Design and switched to Computer-Aided-Design (CAD) in the mid-1980s. When Commodore computers came out in the late 1970s, Ed purchased one and immediately became hooked on computers. ![]() After high school graduation, he became a Journeyman Tool & Die Maker. Steve loves travel, cruises, beaches, movies and he occasionally plays drums in a church praise and worship band.Įd was born and raised in Rochester, NY. Steve has three children and lives in Vero Beach Florida where he is very involved in community organizations such as the Indian River County Chamber of Commerce, Vero Beach Christian Business Association, and Vero Business For Business Networking. Many agreed to have him improve their websites, and Positive Design was born. He started doing research and contacting business owners that could use his help. One day while doing this task, he had an idea that there were likely many thousands of websites for small businesses across the United States that needed to be redesigned and improved. ![]() After that, working for a major ISP company, he was tasked with redesigning their unprofessional intranet web pages into an attractive and consistent corporate standard. One of his first jobs after college was creating websites for Mobil Corporation. After a year and half, he transferred to Humboldt State University where he earned a Bachelor's degree in applied mathematics with emphasis in computer science. ).Steve grew up in San Pedro California and started attending UC Santa Barbara in 1990. (Funded by Sanofi and Regeneron Pharmaceuticals ODYSSEY OUTCOMES number, NCT01663402. 2.1% in the placebo group).Īmong patients who had a previous acute coronary syndrome and who were receiving high-intensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than among those who received placebo. The incidence of adverse events was similar in the two groups, with the exception of local injection-site reactions (3.8% in the alirocumab group vs. The absolute benefit of alirocumab with respect to the composite primary end point was greater among patients who had a baseline LDL cholesterol level of 100 mg or more per deciliter than among patients who had a lower baseline level. A total of 334 patients (3.5%) in the alirocumab group and 392 patients (4.1%) in the placebo group died (hazard ratio, 0.85 95% CI, 0.73 to 0.98). A composite primary end-point event occurred in 903 patients (9.5%) in the alirocumab group and in 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85 95% confidence interval, 0.78 to 0.93 P<0.001). The median duration of follow-up was 2.8 years. The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. We conducted a multicenter, randomized, double-blind, placebo-controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low-density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non-high-density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high-intensity dose or at the maximum tolerated dose. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy. Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |